Tianjin Pharmaceutical Da Ren Tang (SGX:T14, SHA:600329) plans to provide an 832.7 million yuan guarantee for its subsidiary Tianjin Zhongxin Medicine, according to a Wednesday filing on the Singapore Exchange.
The guarantee is part of a broader plan to support Tianjin Zhongxin's ongoing operations and facilitate the restructuring of its entrusted loans.
The guarantee will be provided as part of a joint and several liability agreement with Tianjin Pharmaceutical Holding, another shareholder in Tianjin Zhongxin.
It corresponds to Tianjin Pharmaceutical Da Ren Tang's 43.35% stake in Tianjin Pharmaceutical Group Taiping Medicine.
The guarantee requires shareholder approval at an upcoming extraordinary general meeting.
Price (SGD): S$2.05, Change: S$+0.020, Percent Change: +0.99%
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。